Voyager Therapeutics price target lowered to $7 from $8 at Wedbush

Wedbush lowered the firm’s price target on Voyager Therapeutics to $7 from $8 and keeps a Neutral rating on the shares. Most notable in the Q2 financial results update, all key pipeline development programs remain on track, the firm says. With dosing in the tau program starting in healthy volunteers, management reiterated timing for PET imaging data in Alzheimer’s patients by the second half of 2026. For Wedbush’s part, it looks for clinical proof-of-concept data before getting more constructive on the program.